Zhang X-M, Huang G-W, Tian Z-H, Ren D-L, Wilson JX
They work by signaling cells to produce proteins like collagen and elastin, which are important for maintaining skin structure and elasticity
Units = (dose concentration) 100
Personal Opinion: Having reviewed extensive research on peptides for hair applications, I find GHK-Cu particularly compelling because it addresses hair loss through so many different pathways simultaneously
Peptide degradation products can bind to c-Met receptors without activating downstream signaling
Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)